SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis - Top-Institutions - MDSpire

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

A nationwide cohort study found lower rates of cardiorenal complications and hepatic decompensation

  • By

  • Henry Thomas

  • March 10, 2026

  • 2 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Endocrinology
    • Hepatology
    • Nephrology
    • Cardiology

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Endocrinology
    • Hepatology
    • Cardiology

  • #3

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Endocrinology
    • Hepatology
    • Nephrology

  • #4

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Endocrinology
    • Hepatology
    • Cardiology

  • #5

    Taipei Veterans General Hospital
    Taipei Veterans General Hospital

    Taipei, Taiwan

    Key Differentiators

    • Endocrinology
    • Hepatology
    • Epidemiology

Original Source(s)

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

  • by Henry Thomas

  • March 10, 2026

Related Content

Metabolomic signatures mediate the association between physical frailty and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study

Diabetes Risk Scores: Beyond Glucose

Multi-ancestry polygenic models identify high-risk patients traditional screening may miss.

Association Between Metabolic Clusters and Microbial Age in High-Risk Populations for Diabetes and Their Potential Impact on Cardiovascular Disease Risk: Cross-Sectional Observational Study